# OnCo record mobocertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mobocertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mobocertinib" ;
  schema:name "Mobocertinib"@en ;
  schema:description "Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."@en ;
  schema:url <https://onco.cc/drugs/mobocertinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mobocertinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q105338009> ;
  schema:citation <https://en.wikipedia.org/wiki/Mobocertinib> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule EGFR exon 20 insertion TKI (irreversible)" ;
  schema:alternateName "Exkivity" ;
  onco:approval "US 2021: EGFR exon 20 insertion NSCLC after platinum" ;
  onco:acceleratedApproval "US 2021-09-15: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/egfr-exon20-insertion/> ;
  onco:trials <https://onco.cc/trials/nct04129502/> .